Connecting the dots: Carrier screening and the Genetic Information Nondiscrimination Act in the United States.
Journal
Prenatal diagnosis
ISSN: 1097-0223
Titre abrégé: Prenat Diagn
Pays: England
ID NLM: 8106540
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
17
06
2023
received:
01
02
2023
accepted:
27
06
2023
medline:
15
8
2023
pubmed:
1
7
2023
entrez:
1
7
2023
Statut:
ppublish
Résumé
To highlight the possibility of genetic discrimination in the United States with respect to carrier screening under limitations of the Genetic Information Nondiscrimination Act (GINA) and to encourage providers to educate patients about this possibility during pretest counseling. Review of current professional guidelines and practice resources regarding the necessary components of pretest counseling for carrier screening in the context of GINA's limitations and the potential impact of carrier screening results on life, long-term care and disability insurance. Current practice resources advise that patients in the United States should be informed that their employer or health insurance company generally cannot use their genetic information during the underwriting process. However, these resources do not elaborate on GINA's limitations or explain why there may be adverse consequences to patients regarding these limitations. Studies have demonstrated significant gaps in provider knowledge of GINA, especially for those without formal genetic training. Enhanced education and provision of GINA educational resources for providers and patients will help ensure that patients have the opportunity to prioritize their insurance needs prior to undergoing carrier screening.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1142-1149Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Haque IS, Lazarin GA, Kang HP, Evans EA, Goldberg JD, Wapner RJ. Modeled fetal risk of genetic diseases identified by expanded carrier screening. JAMA, J Am Med Assoc. 2016;316(7):734-742. https://doi.org/10.1001/jama.2016.11139
Dugoff L. Carrier screening for single gene disorders. Top Obstet Gynecol. 2021;41
Clevenger SK, Brandt JS, Khan SP, et al. Rate of manifesting carriers and other unexpected findings on carrier screening. Prenat Diagn. 2023;43(1):117-125. https://doi.org/10.1002/pd.6289
Carrier screening in the age of genomic medicine. Obstet Gynecol. 2017;129(3):e35-e40.
Gregg AR, Aarabi M, Klugman S, et al. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23(10):1793-1806. https://doi.org/10.1038/s41436-021-01203-z
Grody WW, Thompson BH, Gregg AR, et al. ACMG position statement on prenatal/preconception expanded carrier screening. Genet Med. 2013;15(6):482-483. https://doi.org/10.1097/01.ogx.0000441141.05679.2c
Westemeyer M, Saucier J, Wallace J, et al. Clinical experience with carrier screening in a general population: support for a comprehensive pan-ethnic approach. Genet Med. 2020;22(8):1320-1328. https://doi.org/10.1038/s41436-020-0807-4
Strauss TS, Boniferro E, Brockhoff E, et al. Opening Pandora's box: abnormal genetic carrier screening and need for lifetime follow-up. Am J Obstet Gynecol MFM. 2023;5(3):100820. https://doi.org/10.1016/j.ajogmf.2022.100820
Reiner J, Rosenblum LS, Xin W, Zhou Z, Zhu H, Leach N. Incidental molecular diagnoses and heterozygous risk alleles in a carrier screening cohort. Genet Med. 2023;25(2):100317. https://doi.org/10.1016/j.gim.2022.10.001
Genetic Information Nondiscrimination Act. In: T Congress, ed. H.R.4932008.
Edwards JG, Feldman G, Goldberg J, et al. Expanded carrier screening in reproductive medicine-points to consider: a joint statement of the American College of Medical Genetics and Genomics, American College of Obstetricians and Gynecologists, National Society of Genetic Counselors, Perinatal Quality Foundation, and Society for Maternal-Fetal Medicine. Obstet Gynecol. 2015;125(3):653-662. https://doi.org/10.1097/aog.0000000000000666
Shah PD, Domchek SM. The contemporary landscape of genetic testing and breast cancer: emerging issues. Breast J. 2020;26(8):1549-1555. https://doi.org/10.1111/tbj.13968
Massachusetts Co. An Act to Create a Genetic Bill of Rights.
Florida house of representatives HB 1189. In. Genetic information for insurance purposes 2020.
Seaver LH, Khushf G, King NMP, et al. Points to consider to avoid unfair discrimination and the misuse of genetic information: A statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2022;24(3):512-520. https://doi.org/10.1016/j.gim.2021.11.002
Huizenga CR, Lowstuter K, Banks KC, Lagos VI, Vandergon VO, Weitzel JN. Evolving perspectives on genetic discrimination in health insurance among health care providers. Fam Cancer. 2009;9(2):253-260. https://doi.org/10.1007/s10689-009-9308-y
Monaghan KG, Leach NT, Pekarek D, Prasad P, Rose NC. The use of fetal exome sequencing in prenatal diagnosis: a points to consider document of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2020;22(4):675-680. https://doi.org/10.1038/s41436-019-0731-7
Manickam K, McClain MR, Demmer LA, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23(11):2029-2037. https://doi.org/10.1038/s41436-021-01242-6
Hipp HS, Charen KH, Spencer JB, Allen EG, Sherman SL. Reproductive and gynecologic care of women with fragile X primary ovarian insufficiency (FXPOI). Menopause. 2016;23(9):993-999. https://doi.org/10.1097/gme.0000000000000658
Randi JH, Paul H. Fragile X-associated tremor/ataxia syndrome -- features, mechanisms and management. Nat Rev Neurol. 2016;12(7):403-412. https://doi.org/10.1038/nrneurol.2016.82
Torkzaban M, Haddad A, Baxter JK, Berghella V, Gahl WA, Al-Kouatly HB. Maternal ornithine transcarbamylase deficiency, a genetic condition associated with high maternal and neonatal mortality every clinician should know: A systematic review. Am J Med Genet. 2019;179(10):2091-2100. https://doi.org/10.1002/ajmg.a.61329
van Os NJH, Roeleveld N, Weemaes CMR, et al. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. Clin Genet. 2016;90(2):105-117. https://doi.org/10.1111/cge.12710
Cook L, Schulze J. Connecting Gaucher and Parkinson disease: Considerations for clinical and research genetic counseling settings. J Genet Counsel. 2017;26(6):1165-1172. https://doi.org/10.1007/s10897-017-0123-6
National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic 2023; Version 2.2023; 2023.
Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet. 2000;97(3):189-194. https://doi.org/10.1002/1096-8628(200023)97:3<189::aid-ajmg1036>3.0.co;2-j
Alcalay RN, Dinur T, Quinn T, et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol. 2014;71(6):752-757. https://doi.org/10.1001/jamaneurol.2014.313
Rana HQ, Balwani M, Bier L, Alcalay RN. Age-specific Parkinson disease risk in GBA mutation carriers: information for genetic counseling. Genet Med. 2013;15(2):146-149. https://doi.org/10.1038/gim.2012.107
OMIM. Online Mendelian Inheritance in Man; 2023.
Life F. Life Insurance for Families; 2020. Accessed 31 January 2023. https://fidelitylife.com/life-insurance-basics/life-insurance-101/life-insurance-for-families/
Towbin JA, Hejtmancik JF, Brink P, et al. X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation. 1993;87(6):1854-1865. https://doi.org/10.1161/01.cir.87.6.1854
McCaffrey T, Guglieri M, Murphy AP, Bushby K, Johnson A, Bourke JP. Cardiac involvement in female carriers of Duchenne or Becker muscular dystrophy. Muscle Nerve. 2017;55(6):810-818. https://doi.org/10.1002/mus.25445
Dungan J. Expanded carrier screening: what the reproductive endocrinologist needs to know. Fertil Steril. 2018;109(2):183-189. https://doi.org/10.1016/j.fertnstert.2017.11.030
Lazarin GAMS, Haque ISP. Expanded carrier screening: A review of early implementation and literature. Semin Perinatol. 2016;40(1):29-34. https://doi.org/10.1053/j.semperi.2015.11.005
Lenartz A, Scherer AM, Uhlmann WR, Suter SM, Anderson Hartley C, Prince AER. The persistent lack of knowledge and misunderstanding of the Genetic Information Nondiscrimination Act (GINA) more than a decade after passage. Genet Med. 2021;23(12):2324-2334. https://doi.org/10.1038/s41436-021-01268-w
Lenartz A, Scherer AM, Uhlmann WR, Suter SM, Anderson Hartley C, Prince AER. Correction: the persistent lack of knowledge and misunderstanding of the Genetic Information Nondiscrimination Act (GINA) more than a decade after passage. Genet Med. 2021;23(12):2471. https://doi.org/10.1038/s41436-021-01305-8
Lowstuter KJ, Sand S, Blazer KR. Influence of genetic discrimination perceptions and knowledge on cancer genetics referral practice among clinicians (Genet Med 10, 691-698. Genet Med. 2008;10(10):762.
Nedelcu R, Blazer KR, Schwerin BU, et al. Genetic discrimination: the clinician perspective. Clin Genet. 2004;66(4):311-317. https://doi.org/10.1111/j.1399-0004.2004.00303.x
Freedman AN, Wideroff L, Olson L, et al. US physicians' attitudes toward genetic testing for cancer susceptibility. Am J Med Genet. 2003;120A(1):63-71. https://doi.org/10.1002/ajmg.a.10192
Genetic Alliance and the National Coalition for Health Professional Education in Genetics. Genetic Information Nondiscrimination Act. 2010.